RxDoctor Payments Data

Amanda Lewis, APRN

Family · Lakeland, FLNPI 1679061691

Payments from drug & device makers

$14,684in general payments, 2019–2025

Across 805 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Dexcom, Inc.$827
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$14,55699%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,684 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$67,857
Medicare patients
270
Services billed
1,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$90,372
OzempicSemaglutide53$85,893
JardianceEmpagliflozin19$30,751
Repatha SureclickEvolocumab23$28,718
FarxigaDapagliflozin Propanediol16$21,058
MounjaroTirzepatide16$21,009
Nurtec OdtRimegepant Sulfate12$14,149
Albuterol Sulfate HfaAlbuterol Sulfate54$1,803
SynthroidLevothyroxine Sodium20$1,487
Rosuvastatin Calcium144$1,468
Levothyroxine Sodium133$1,431
Losartan Potassium110$1,183
Gabapentin66$1,128
Atorvastatin Calcium117$1,091
Omeprazole79$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$1,098$104,52091 claims
Novo NordiskOzempic$1,671$85,89353 claims
Boehringer IngelheimJardiance$614$30,75119 claims
AstraZenecaFarxiga$2,536$21,05816 claims
Lilly USA, LLCMounjaro$1,027$21,00916 claims
AbbVieSynthroid$2,226$1,48720 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,431133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →